Clinical Trial Update: Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing patient preference between apalutamide and enzalutamide in recurrent or metastatic hormone-sensitive prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED